When was Profluent Bio founded?

Profluent Bio was founded in 2022 and raised its 1st funding round 1 year after it was founded.

Where is Profluent Bio located?

Profluent Bio is headquartered in Berkeley, United States.

Who is the current CEO of Profluent Bio?

Ali Madani of Profluent Bio. They have also founded 1 company.

How many employees does Profluent Bio have?

As of Sep 30, 2026, the latest employee count at Profluent Bio is 83.

Is Profluent Bio a funded company?

Profluent Bio is a funded company, having raised a total of $150M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 26, 2023.

How much is Profluent Bio worth?

The latest valuation of Profluent Bio is $***** as of Nov 20, 2025.

When was the latest funding round of Profluent Bio?

Profluent Bio's latest funding was a $***** Series B round on Nov 19, 2025, with participation from 5 investors. Its primary sector is Generative AI. In United States, the Generative AI sector has seen $255B in funding in 2026 to date.

Where does Profluent Bio rank among its competitors?

Profluent Bio ranks 3rd amongst 70 active competitors, of which 40 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Converge, which secured $2.5M in Jun, 2026.

Who are the top competitors of Profluent Bio?

Profluent Bio's top competitors include Generate Biomedicines, Cradle and Nimbus Therapeutics. Among them, Converge secured the most recent funding round in June, 2026.

Profluent Bio - 2026 Company Profile, Team, Funding & Competitors

Profluent Bio is a series B company based in Berkeley (United States), founded in 2022 by Ali Madani and Alexander Meeske. It operates as a Provider of an artificial intelligence-based protein design platform. Profluent Bio has raised $150M in funding from investors like Insight Partners, Spark Capital and Bezos Expeditions, with a current valuation of $*****. The company has 70 active competitors, including 40 funded and 4 that have exited. Its top competitors include companies like Generate Biomedicines, Cradle and Nimbus Therapeutics.

Company Details

Provider of an artificial intelligence-based protein design platform. It uses deep generative models to design novel, functional proteins that can be used in drug discovery.

Website: www.profluent.bio/
Email ID: *****@profluent.bio

Key Metrics

Founded Year

2022

Location

Berkeley, United States

Stage

Series B

Total Funding

$150M in 3 rounds

Latest Funding Round

Series B, Nov 19, 2025, $*****

Post Money Valuation

$***** as on Nov 20, 2025

Investors

Insight Partners & 7 more

Ranked

3^rd among 70 active competitors

Employee Count

83 as on Sep 30, 2026

Similar Companies

OpenEvidence & 2941 more

View Profluent Bio's full profile

Profluent Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Profluent Bio Inc. CIN: 88-3009864 , United States, Active		-	-	-

Profluent Bio has raised a total funding of $150M over 3 rounds. Its first funding round was on Jan 26, 2023. Its latest funding round was a Series B round on Nov 19, 2025 for $*****. 5 investors participated in its latest round. Profluent Bio has 8 institutional investors.

Here is the list of recent funding rounds of Profluent Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 19, 2025	6709512	Series B	8736672	1460489	4940666	3811477
Mar 21, 2024	6567747	Series A	7644598	8759537	1459115	Insight Partners & 1 more
Jan 26, 2023	1814997	Seed	1055290	4062928	Insight Partners	Air Street Capital & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Profluent Bio's funding rounds and investors

The founders of Profluent Bio are Ali Madani and Alexander Meeske. Ali Madani is the CEO of Profluent Bio.

Here are the details of Profluent Bio's key team members:

Ali Madani: Co-Founder & CEO of Profluent Bio.
Contact Info: 1 email address
Alexander Meeske: Co-Founder of Profluent Bio.
Contact Info: 1 email address

View details of Profluent Bio's Founder profiles and Board Members

Profluent Bio's employee count trend

Profluent Bio has 83 employees as of Sep 26. Here is Profluent Bio's employee count trend over the years:

Uncover Profluent Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Profluent Bio include Generate Biomedicines, Cradle and Nimbus Therapeutics. Here is the list of Top 10 competitors of Profluent Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Generate Biomedicines 2018, Somerville (United States), Public	Developer of a platform for generating novel protein-based therapeutic modalities	$693M	Pictet Group, NVentures & 14 others	67/100
2nd	Cradle 2021, Zurich (Switzerland), Series B	Provider of chemoproteomics solutions for protein design and development	$103M	Index Ventures, Kindred Capital & 7 others	67/100
3rd	Profluent Bio 2022, Berkeley (United States), Series B	Provider of an artificial intelligence-based protein design platform	$150M	Spark Capital, Altimeter Capital & 6 others	66/100
4th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	64/100
5th	EvolutionaryScale 2023, New York City (United States), Seed	Provider of an AI models for protein design	$142M	Lux Capital, Amazon & 3 others	64/100
6th	Eikon 2019, Millbrae (United States), Public	Protein tracking and measuring tool for drug discovery	$1.16B	The Column Group, T. Rowe Price & 23 others	64/100
7th	Frontier Medicines 2018, San Francisco (United States), Series C	Developer of a bioinformatics platform for drug development and chemoproteomics	$236M	Deerfield, RA Capital Management & 11 others	58/100
8th	Seismic 2019, Watertown (United States), Series B	AI-assisted platform for drug discovery and development	$247M	Lightspeed Venture Partners, Bessemer Venture Partners ... & 12 others	58/100
9th	AI Proteins 2021, Boston (United States), Series A	Developer of de novo designed miniproteins for therapeutic applications	$59.7M	Mission BioCapital, Sante & 4 others	58/100
10th	Converge 2024, Wilmington (United States), Series A	Developer of GenAI computational tools for drug discovery and manufacturing	$30.5M	Bessemer Venture Partners, TLV Partners & 3 others	56/100